Amoxicillin Market Analysis By Recent Trends, Development | Industry Growth By Regions To 2026
According to the current analysis of Reports and Data, the global Amoxicillin market was valued at USD 4,408.1 million in 2018 and is expected to reach USD 4,962.6 million by the year 2026, at a CAGR of 1.5%. The amoxicillin antibiotics is a generic category of drug. It is also known by the name Amoxil and is usually administered in the treatment involving bacterial infections. The compound belongs to the β-lactam drug class of antibiotics. The amoxicillin medication is used in treating infections such as, pneumonia, ear infections, bronchitis, sinusitis, infections of the skin, and urinary tract infection (UTI). Its use for UTI is found to be used most than any other antibiotics. This antibiotic can also be taken in combinations with other drugs, such as amoxicillin and clavulanate potassium, it is used for treating bacterial infections mentioned before. The use of amoxicillin antibiotics for tooth infection is also popular. The increasing frequencies of bacterial infections in low-income countries, developing countries and other parts of the world will be the most significant factor in driving the growth of this market. Also the increasing research and applications of combination drugs with this medication will fasten the progress of the market. Furthermore, these medicines are safe to be taken together with birth control pills. Although, the possible side effects of amoxicillin are expected to hamper the development of the market to some extent.
The market is segmented on the basis of the diseases, the route administration, drug formulation, and distribution channels involved in distributing the medicine. The medication is available in tablet, capsule, suspension, syrup, and powder form, through hospital pharmacies, drug stores, retail stores and online pharmacies. It can be taken orally and through intravenous route as well. Some specific combinational medications are also prescribed for pregnant women. It includes, erythromycin or clarithromycin in combination with amoxicillin if the patient is pregnant with moderately severe infection; and Co-amoxiclav with clarithromycin, or erythromycin if the patient is pregnant with high-severity infection.
On the basis of geography, the North America segment is observed to be the fastest growing market, owing it to the growing number of clinical trials, research and development scenarios in the region. Europe is expected to perform good with Asia Pacific expected to growth with the highest CAGR across the world. Europe segment growth is anticipated to get impeded to some extends due to the announcement by government about its decision to reduce antibiotic prescriptions by around 15% this year, as part of a new plan to control antimicrobial resistance by 2040.
Furthermore, increased government initiatives for encouraging the use of this medicine, availability of research funds from private as well as public bodies, improvement in the reimbursement scenario, and rising awareness about multiple benefits of amoxicillin prescription are among the key factors propelling the growth of the market. Other medication alternatives of antibiotic amoxicillin are anticipated to impede the market growth. However according to a recent update from Journal of the American College of Cardiology it was found that Cipro or Ciprofloxacin, owns huge risk of escalating a heart-valve problem than another broad-spectrum antibiotic specifically amoxicillin.
To identify the key trends in the industry, click on the link below:
https://www.reportsanddata.com/report-detail/amoxicillin-market
